Anavex gets approval to begin phase 2b/3 trial of Alzheimer’s disease treatment

This article was originally published here

Anavex Life Sciences has secured approval from the Australian Human Research Ethics Committee to begin its phase 2b/3 trial of Anavex 2-73 to treat early Alzheimer’s disease.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply